Evidence map›Paper›PMID 37359748›Full record

ArticleOne health (Amsterdam, Netherlands)2023

Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan.

Seiya Yamayoshi, Mutsumi Ito, Kiyoko Iwatsuki-Horimoto, Atsuhiro Yasuhara, Moe Okuda, Taiki Hamabata, Jurika Murakami, Calvin Duong, Tsukasa Yamamoto, Yudai Kuroda and 2 more

Open access · goldAbstract read
In one paragraph

Article in One health (Amsterdam, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Ultrafast and high-throughput immunoassay assay to detect anti-SARS-CoV-2 IgG antibodies in dogs and cats.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Seiya YamayoshiDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Mutsumi ItoDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Atsuhiro YasuharaDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Moe OkudaDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Taiki HamabataDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Jurika MurakamiDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Calvin DuongDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
Tsukasa YamamotoDepartment of Veterinary Science, National Institute of Infectious Diseases, Japan.
Yudai KurodaDepartment of Veterinary Science, National Institute of Infectious Diseases, Japan.
Ken MaedaDepartment of Veterinary Science, National Institute of Infectious Diseases, Japan.
Yoshihiro KawaokaDivision of Virology, Institute of Medical Science, University of Tokyo, Japan.
National Institute of Infectious Diseases · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to circulate in humans since its emergence in 2019. While infection in humans continues, numerous spillover events to at least 32 animal species, including companion and zoo animals, have been reported. Since dogs and cats are highly susceptible to SARS-CoV-2 and have direct contact with their owners and other household members, it is important to know the prevalence of SARS-CoV-2 in dogs and cats. Here, we established an ELISA to detect serum antibodies against the receptor-binding domain and the ectodomain of the SARS-CoV-2 spike and nucleocapsid proteins. Using this ELISA, we assessed seroprevalence in 488 dog serum samples and 355 cat serum samples that were collected during the early pandemic period (between May and June of 2020) and 312 dog serum samples and 251 cat serum samples that were collected during the mid-pandemic period (between October 2021 and January 2022). We found that two dog serum samples (0.41%) collected in 2020, one cat serum sample (0.28%) collected in 2020, and four cat serum samples (1.6%) collected in 2021 were positive for antibodies against SARS-CoV-2. No dog serum samples collected in 2021 were positive for these antibodies. We conclude that the seroprevalence of SARS-CoV-2 antibodies in dogs and cats in Japan is low, suggesting that these animals are not a major SARS-CoV-2 reservoir.

Indexed as

CatCOVID-19DogSARS-CoV-2Seroprevalence

Identifiers

PMID37359748
PMCPMC10279464
OpenAlexW4381251308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.